Axcan reports Urso Phase II data

Axcan (TSE:AXP; AXCA) said its Urso 250 ursodeoxycholic acid had no statistically significant difference in mean number of recurring polyps and average polyp size compared to placebo in a Phase II trial to prevent colorectal adenomatous polyps. The final analysis included 594 of the 716 patients that completed the one-year follow-up period. ...